FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christopher Ryan

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Christopher W Ryan; Charles Williams; Antonio Lopez-Pousa; Chacon Matias; Mary Alice Miller; Mark Agulnik; Dinesh P de Alwis; Sabine Ermisch; Robert Ilaria; Christopher Kaiser; M L Keohan
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Toni K Choueiri; Mario A Eisenberger; Noah M Hahn; Thomas E Hutson; Susanna Jacobus; Glenn J Bubley; Geoffrey C Buckle; William Y Kim; Stephanie C Morrissey; Amir Mortazavi; Daniel P Petrylak; David I Quinn; Jonathan E Rosenberg; Robert W Ross; Christopher W Ryan; Guru Sonpavde; Mary-Ellen Taplin; Ulka Nitin Vaishampayan; Evan Y Yu; Philip W Kantoff
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Margaret von Mehren; Vivien Bramwell; George D Demetri; John R Goldblum; Cathryn Rankin; Christopher W Ryan; Ernest Borden
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christopher Ryan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christopher W Ryan; Charles Williams; Antonio Lopez-Pousa; Chacon Matias; Mary Alice Miller; Mark Agulnik; Dinesh P de Alwis; Sabine Ermisch; Robert Ilaria; Christopher Kaiser; M L Keohan
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Investigational new drugs 2013;31(1):145-51.
2012: Toni K Choueiri; Mario A Eisenberger; Noah M Hahn; Thomas E Hutson; Susanna Jacobus; Glenn J Bubley; Geoffrey C Buckle; William Y Kim; Stephanie C Morrissey; Amir Mortazavi; Daniel P Petrylak; David I Quinn; Jonathan E Rosenberg; Robert W Ross; Christopher W Ryan; Guru Sonpavde; Mary-Ellen Taplin; Ulka Nitin Vaishampayan; Evan Y Yu; Philip W Kantoff
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):507-12.
2012: Margaret von Mehren; Vivien Bramwell; George D Demetri; John R Goldblum; Cathryn Rankin; Christopher W Ryan; Ernest Borden
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Cancer 2012;118(3):770-6.
2011: Christopher W Ryan; Jacqueline Vuky; Joseph S Chan; Zunqiu Chen; Tomasz M Beer; Deirdre Nauman
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Investigational new drugs 2011;29(2):374-9.
2010: Tomasz M Beer; Charles Ryan; Joshi J Alumkal; Christopher W Ryan; Janine Sun; Kristine M Eilers
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Anti-cancer drugs 2010;21(4):433-8.
2010: Walter M Stadler; Robert A Figlin; David F McDermott; Janice P Dutcher; Jennifer J Knox; Wilson H Miller; John D Hainsworth; Charles A Henderson; Jeffrey R George; Julio Hajdenberg; Tamila L Kindwall-Keller; Marc S Ernstoff; Harry A Drabkin; Brendan D Curti; Luis Chu; Christopher W Ryan; Sebastien J Hotte; Chenghua Xia; Lisa Cupit; Ronald M Bukowski
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Cancer 2010;116(5):1272-80.
2010: Ronald M Bukowski; Walter M Stadler; David F McDermott; Janice P Dutcher; Jennifer J Knox; Wilson H Miller; John D Hainsworth; Charles A Henderson; Julio Hajdenberg; Tamila L Kindwall-Keller; Marc S Ernstoff; Harry A Drabkin; Brendan D Curti; Luis Chu; Christopher W Ryan; Sebastien J Hotte; Chenghua Xia; Lisa Cupit; Robert A Figlin
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Oncology 2010;78(5-6):340-7.
2009: Christopher W Ryan
Editorial comment.
The Journal of urology 2009;182(6):2675; dscussion 2676.
2009: Mary-Ellen Taplin; Meredith M Regan; Yoo-Joung Ko; Glenn J Bubley; Stephen E Duggan; Lillian Werner; Tomasz M Beer; Christopher W Ryan; Paul Mathew; Shi-Ming Tu; Samuel R Denmeade; William K Oh; Oliver Sartor; Christos S Mantzoros; Roger Rittmaster; Philip W Kantoff; Steven P Balk
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7099-105.
2009: Jonathan E Rosenberg; Charles J Ryan; Vivian Weinberg; David C Smith; Maha Hussain; Tomasz M Beer; Christopher W Ryan; Paul Mathew; Lance C Pagliaro; Andrea L Harzstark; Jeremy Sharib; Eric J Small
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2772-8.
2008: Joseph S Chan; Tomasz M Beer; David I Quinn; Jacek Pinski; Mark Garzotto; Mitchell H Sokoloff; Daniel R Dehaze; Christopher W Ryan
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
BJU international 2008;102(11):1601-6.
2008: Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H C Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5360-7.
2008: Tomasz M Beer; Bryan Goldman; Timothy W Synold; Christopher W Ryan; Lakshmi S Vasist; Peter J Van Veldhuizen; Shaker R Dakhil; Primo Lara; Anibal Drelichman; Maha Hussain; E David Crawford
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clinical genitourinary cancer 2008;6(2):103-9.
2008: Tomasz M Beer; Alshad S Lalani; Stella Lee; Motomi Mori; Kristine M Eilers; John G Curd; W David Henner; Christopher W Ryan; Peter Venner; J Dean Ruether; Kim N Chi
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Cancer 2008;112(11):2377-83.
2008: Christopher W Ryan; Anthony G Montag; Janet R Hosenpud; Brian L Samuels; James B Hayden; Arthur Y Hung; Atiya Mansoor; Terrance D Peabody; Arno J Mundt; Samir Undevia
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Cancer 2008;112(11):2432-9.
2008: Tomasz M Beer; Bryan Goldman; Craig Nichols; Daniel P Petrylak; Manoj Agarwal; Christopher W Ryan; E David Crawford
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Clinical genitourinary cancer 2008;6(1):36-9.
2008: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; ROBERT G MAKI; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):626-32.
2008: Robert W Ross; Tomasz M Beer; Susanna Jacobus; Glenn J Bubley; Mary-Ellen Taplin; Christopher W Ryan; Jiaoti Huang; William K Oh
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Cancer 2008;112(3):521-6.
2008: Ron S Israeli; Christopher W Ryan; Laura L Jung
Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
The Journal of urology 2008;179(2):414-23.
2008: Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Kim N Chi; James Young; W David Henner
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Cancer 2008;112(2):326-30.
2007: Tomasz M Beer; Christopher W Ryan
The hazards of intermediate endpoints.
Cancer 2007;110(9):1877-9.
2007: R Bruce Montgomery; Peter S Nelson; Daniel Lin; Christopher W Ryan; Mark Garzotto; Tomasz M Beer
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Cancer 2007;110(5):996-1002.
2007: Christopher W Ryan; Bryan H Goldman; Primo Lara; Philip C Mack; Tomasz M Beer; Catherine M Tangen; Dianne Lemmon; Chong-Xian Pan; Harry A Drabkin; E David Crawford
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3296-301.
2007: Christopher W Ryan; Dezheng Huo; James W Stallings; Ronald L Davis; Tomasz M Beer; Laura T McWhorter
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Urology 2007;70(1):122-6.
2007: Christopher W Ryan; Dezheng Huo; Kathryn Bylow; Laurence M Demers; Walter M Stadler; Tara O Henderson; Nicholas J Vogelzang
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
BJU international 2007;100(1):70-5.
2007: Adam S Kibel; Eli Rosenbaum; Michael W Kattan; Joel Picus; Robert Dreicer; Eric A Klein; Gurkamal S Chatta; Joel B Nelson; Robert S DiPaola; Bruce J Roth; Michael S Cookson; George Wilding; David F Jarrard; Tomasz M Beer; Christopher W Ryan; Daniel P Petrylak; Mitchell C Benson; Alan W Partin; Elizabeth Garrett-Mayer; Mario A Eisenberger
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
2007: Tomasz M Beer; Milind Javle; Christopher W Ryan; Mark Garzotto; Gilbert N Lam; Alvin Wong; W David Henner; Candace S Johnson; Donald L Trump
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.
Cancer chemotherapy and pharmacology 2007;59(5):581-7.
2007: Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Charles H Redfern; Louis Fehrenbacher; Mansoor N Saleh; David M Waterhouse; Michael A Carducci; Daniel Vicario; Robert Dreicer; Celestia S Higano; Frederick R Ahmann; Kim N Chi; W David Henner; Alan Arroyo; Fong W Clow
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):669-74.
2006: Tomasz M Beer; Peter M Venner; Christopher W Ryan; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Kim N Chi; John G Curd; Thomas G Deloughery
High dose calcitriol may reduce thrombosis in cancer patients.
British journal of haematology 2006;135(3):392-4.
2006: Christopher W Ryan; M Eileen Dolan; Bruce B Brockstein; Roger McLendon; Shannon M Delaney; Brian L Samuels; Edem S Agamah; Everett E Vokes
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
Cancer chemotherapy and pharmacology 2006;58(5):634-9.
2006: Tomasz M Beer; Christopher W Ryan; Gajanan Bhat; Marc Garnick
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
Anti-cancer drugs 2006;17(9):1075-9.
2006: Christopher W Ryan; Dezheng Huo; Laurence M Demers; Tomasz M Beer; Leo V Lacerna
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
The Journal of urology 2006;176(3):972-8; discussion 978.
2006: Jonathan Q Purnell; Lisa B Bland; Mark Garzotto; Dianne Lemmon; Emily M Wersinger; Christopher W Ryan; John D Brunzell; Tomasz M Beer
Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.
Journal of lipid research 2006;47(2):349-55.
2006: Tomasz M Beer; Lisa B Bland; Joseph R Bussiere; Michelle B Neiss; Emily M Wersinger; Mark Garzotto; Christopher W Ryan; Jeri S Janowsky
Testosterone loss and estradiol administration modify memory in men.
The Journal of urology 2006;175(1):130-5.
2005: Nancy B Davis; Christopher W Ryan; Walter M Stadler; Nicholas J Vogelzang
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
BJU international 2005;96(6):787-90.
2005: Natasha M Tiffany; Christopher W Ryan; Mark Garzotto; Emily M Wersinger; Tomasz M Beer
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
The Journal of urology 2005;174(3):888-92.
2005: Mitchell H Sokoloff; Siamak Daneshmand; Christopher W Ryan
Current clinical trials in renal cell carcinoma.
Urologic oncology 2005;23(4):289-92.
2005: Christopher W Ryan; Walter M Stadler; Nicholas J Vogelzang
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
BJU international 2005;95(7):963-8.
2005: Andrew S Artz; Walter M Stadler; Nicholas J Vogelzang; Todd M Zimmerman; Christopher W Ryan
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
American journal of clinical oncology 2005;28(2):109-13.
2005: Lisa B Bland; Mark Garzotto; Thomas G Deloughery; Christopher W Ryan; Kathryn G Schuff; Emily M Wersinger; Dianne Lemmon; Tomasz M Beer
Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
Cancer 2005;103(4):717-23.
2005: Supriya Gupta; Ann M Mauer; Christopher W Ryan; David A Taber; Brian L Samuels; Gini F Fleming
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
American journal of clinical oncology 2005;28(1):65-9.
2004: Christopher W Ryan; Nicholas J Vogelzang; Everett E Vokes; Hedy L Kindler; Samir D Undevia; Rod A Humerickhouse; Amy K André; Qiang Wang; Robert A Carr; Mark J Ratain
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4406-11.
2004: Walter M Stadler; Dingcai Cao; Nicholas J Vogelzang; Christopher W Ryan; Kristin Hoving; Russell Wright; Theodore Karrison; Everett E Vokes
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3365-70.
2004: Nancy B Davis; David A Taber; Rafat H Ansari; Christopher W Ryan; Christopher George; Everett E Vokes; Nicholas J Vogelzang; Walter M Stadler
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):115-9.
2003: John Villano; Christopher W Ryan
Patients presenting with CNS lesions. Case 2. Subdural presentation of recurrent breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(21):4060-2.
2003: Peter C Wu; Alex Langerman; Christopher W Ryan; John Hart; Susan Swiger; Mitchell C Posner
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Surgery 2003;134(4):656-65; discussion 665-6.
2003: Christopher W Ryan
Informed consent needed from students.
Family medicine 2003;35(9):614; author reply 614.
2003: Walter M Stadler; Dezheng Huo; Christopher George; Ximing Yang; Christopher W Ryan; Theodore Karrison; Todd M Zimmerman; Nicholas J Vogelzang
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
The Journal of urology 2003;170(4 Pt 1):1141-5.
2003: Christopher W Ryan
Statistics to assess patient satisfaction with primary care called into question.
The Journal of family practice 2003;52(5):392-3; author reply 393.
2003: Sunati Sahoo; Christopher W Ryan; Wendy Recant; Ximing J Yang
Angiosarcoma masquerading as embryonal carcinoma in the metastasis from a mature testicular teratoma.
Archives of pathology & laboratory medicine 2003;127(3):360-3.
2002: D K Park; Christopher W Ryan; M Eileen Dolan; Nicholas J Vogelzang; Walter M Stadler
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
Cancer chemotherapy and pharmacology 2002;50(2):160-2.
2002: Christopher W Ryan; Everett E Vokes; Nicholas J Vogelzang; Linda Janisch; Ken Kobayashi; Mark J Ratain
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2002;50(1):1-5.
2002: Christopher W Ryan; Nicholas J Vogelzang; Walter M Stadler
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Cancer 2002;94(10):2602-9.
2001: Christopher W Ryan; Walter M Stadler; Nicholas J Vogelzang
Docetaxel and exisulind in hormone-refractory prostate cancer.
Seminars in oncology 2001;28(4 Suppl 15):56-61.
2000: Christopher W Ryan; Gini F Fleming; Linda Janisch; Mark J Ratain
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
American journal of clinical oncology 2000;23(3):297-300.
2000: Christopher W Ryan; KL Shulman; J M Richards; John W Kugler; Jeffrey A Sosman; Rafat H Ansari; Everett E Vokes; Nicholas J Vogelzang
CI-980 in advanced melanoma and hormone refractory prostate cancer.
Investigational new drugs 2000;18(2):187-91.
2000: Christopher W Ryan; Nicholas J Vogelzang; MC Dumas; T Kuzel; Walter M Stadler
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Cancer 2000;88(6):1317-24.
2000: Christopher W Ryan; N J Vogelzang
Gemcitabine in the treatment of bladder cancer.
Expert opinion on pharmacotherapy 2000;1(3):547-53.
1998: Christopher W Ryan; J Herndon; Nicholas J Vogelzang
A review of chemotherapy trials for malignant mesothelioma.
Chest 1998;113(1 Suppl):66S-73S.